Table I.

Basic information of included studies in the network meta-analysis.

Medicine	Author	Country of patients	A	B	C	D	E	F	G	During (weeks)	outcome	Jadad quality score
Belimumab	Ronald F van Vollenhoven	Sweden, USA, Spain, UK	287	589						52	1	3
Belimumab	A Doria	USA, Europe, Asia	141	435						52	1	4
Belimumab	Fengchun Zhang	China, Japan, Soutd Korea	217	446						52	1	4
Belimumab	RICHARD A. FURIE	UK, USA	86	235						52	1	3
Belimumab	A. Doria	USA, Italy, Japan, Brazil, Netderlands, Nortd Carolina	108	248						52	1	4
Belimumab	Yoshiya Tanaka	Japan	20	39						52	1	4
Belimumab	Richard Furie	Asia, USA, Europe	275	544						52	1	4
Belimumab	Susan Manzi	USA, Canada, Italy, Mexico	287	589						52	1	3
Belimumab	Ellen M	USA	86	235						52	1	4
Belimumab	William Stohl MD	USA, Europe, Australia and Asia	280	556						52	1	4
Belimumab	Vibeke Strand	USA, UK, Spain, Brazil,	287	578						52	1	2
Atacicept	Joan T. Merrill	Latin America, Asia, Soutd Africa, Europe, UK, USA	100		206					52	1	3
Epratuzumab	Megan E. B. Clowse	Nortd America, Latin America, Europe, tde Middle East, India, Korea, China	512			1017				52	1	4
Epratuzumab	Daniel J Wallace	USA, UK, China	38			189				52	1	4
Epratuzumab	Daniel J. Wallace	USA,UK	40			65				52	1	4
Tabalumab	D A Isenberg	USA, Asian	381				757			52	1	4
Tabalumab	J T Merrill	USA, Canada, Mexico, Central America, Soutd America, Asia-Pacific, Africa/Middle East Europe	376				752			52	1	4
Tabalumab	Yoshiya Tanaka	Japanese	15				15			52	1	4
Rituximab	JT Merrill	UK,USA	88					169		52	1	3
Blisibimod	Joan T Merrill	Belarus, Brazil, Colombia, Georgia, Guatemala, China, Korea, Singapore, Malaysia, Mexico, Russia, Sri Lanka, Thailand and the Philippines	197						245	52	2	4
Blisibimod	R A Furie	Argentina , Brazil, Chile, Colombia, China, India, Mexico, Peru, the Philippines, USA	269						277	52	2	4

1: SIR4; 2: SIR6. Placebo: A; Belimumab: B; Atacicept: C; Epratuzumab: D; Tabalumab: E; Rituximab: F; Blisibimod: G.